{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:29:22Z","timestamp":1790771362709,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recombinant human pentraxin-2 (rhPTX-2) significantly decreased decline in percent predicted forced vital capacity (FVC) and stabilized 6-min walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF) during the 28-week, placebo-controlled, randomized period of the Phase II PRM-151\u2013202 study. Interim (76-week) data from the open-label extension (OLE) demonstrated sustained safety and efficacy with rhPTX-2 treatment. Here, we present the entire long-term OLE safety and efficacy data to 128\u00a0weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients who completed the randomized PRM-151\u2013202 study period were eligible for the OLE, during which all patients received rhPTX-2, having started rhPTX-2 (i.e., crossed from placebo) or continued rhPTX-2 after Week 28. rhPTX-2 was administered in 28-week cycles, with 10\u00a0mg\/kg intravenous infusions (60\u00a0min) on Days 1, 3, and 5 in the first week of each cycle, then one infusion every 4\u00a0weeks up to Week 128. The OLE primary objective was to assess the long-term safety and tolerability of rhPTX-2. Other outcomes included FVC, 6MWD, and patient-reported outcomes (descriptive analysis).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All 111 patients who completed the randomized period entered the OLE (n\u2009=\u200937 started rhPTX-2; n\u2009=\u200974 continued rhPTX-2); 57 (51.4%) completed to Week 128. The treatment-emergent adverse event (TEAE) profile was consistent with the randomized period, with the majority of TEAEs graded mild or moderate. Serious TEAEs occurred in 47 patients (42.3%), most frequently IPF (n\u2009=\u200911; 9.9%), pneumonia (n\u2009=\u20097; 6.3%), and acute respiratory failure (n\u2009=\u20093; 2.7%). Three patients underwent lung transplantation. Most serious TEAEs (and all 14 fatal events) were considered unrelated to rhPTX-2 treatment. For patients starting vs continuing rhPTX-2, mean (95% confidence interval) changes from baseline to Week 128 were, respectively,\u2009\u2212\u20096.2% (\u2212\u20097.7;\u2009\u2212\u20094.6) and\u2009\u2212\u20095.7% (\u2212\u20098.0;\u2009\u2212\u20093.3) for percent predicted FVC and\u2009\u2212\u200936.3\u00a0m (\u2212\u200965.8;\u2009\u2212\u20096.9) and\u2009\u2212\u200928.9\u00a0m (\u2212\u200954.3;\u2009\u2212\u20093.6) for 6MWD; however, conclusions were limited by patient numbers at Week 128.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Long-term treatment (up to 128\u00a0weeks) with rhPTX-2 was well tolerated in patients with IPF, with no new safety signals emerging in the OLE. The limited efficacy data over 128\u00a0weeks may suggest a trend towards a treatment effect.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> NCT02550873; EudraCT 2014-004782-24.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-02047-0","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T11:03:06Z","timestamp":1653130986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-6643","authenticated-orcid":false,"given":"Ganesh","family":"Raghu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Hamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Whitney","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S.","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Vasakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Pesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle E.","family":"Antin-Ozerkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith C.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Richeldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"issue":"5","key":"2047_CR1","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"issue":"147","key":"2047_CR2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0062-2017","volume":"27","author":"L Plantier","year":"2018","unstructured":"Plantier L, Cazes A, Dinh-Xuan AT, Bancal C, Marchand-Adam S, Crestani B. Physiology of the lung in idiopathic pulmonary fibrosis. Eur Respir Rev. 2018;27(147): 170062.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"2047_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12931-019-1020-3","volume":"20","author":"M Kreuter","year":"2019","unstructured":"Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019;20(1):59.","journal-title":"Respir Res"},{"key":"2047_CR4","unstructured":"European Medicines Agency. Summary of Product Characteristics - Esbriet (pirfenidone) 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/esbriet-epar-product-information_en.pdf."},{"key":"2047_CR5","unstructured":"European Medicines Agency. Summary of Product Characteristics - Ofev (nintedanib) 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ofev-epar-product-information_en.pdf."},{"key":"2047_CR6","unstructured":"Food and Drug Administration. Summary review of regulatory action - Ofev\u00ae2014 24 June 2021. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205832Orig1s000SumR.pdf."},{"key":"2047_CR7","unstructured":"Food and Drug Administration. Summary review of regulatory action - Esbriet\u00ae2014 24 June 2021. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/022535Orig1s000SumR.pdf."},{"issue":"3","key":"2047_CR8","first-page":"S17","volume":"23","author":"M Fisher","year":"2017","unstructured":"Fisher M, Nathan SD, Hill C, Marshall J, Dejonckheere F, Thuresson P-O, et al. Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2017;23(3):S17\u201324.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"2047_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000397","volume":"6","author":"L Lancaster","year":"2019","unstructured":"Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019;6(1): e000397.","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"2047_CR10","doi-asserted-by":"publisher","first-page":"1902279","DOI":"10.1183\/13993003.02279-2019","volume":"56","author":"J Behr","year":"2020","unstructured":"Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020;56(2):1902279.","journal-title":"Eur Respir J"},{"issue":"22","key":"2047_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"2047_CR12","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"22","key":"2047_CR13","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1001\/jama.2018.6129","volume":"319","author":"G Raghu","year":"2018","unstructured":"Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA. 2018;319(22):2299\u2013307.","journal-title":"JAMA"},{"issue":"4","key":"2047_CR14","doi-asserted-by":"publisher","first-page":"1701209","DOI":"10.1183\/13993003.01209-2017","volume":"50","author":"G Raghu","year":"2017","unstructured":"Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J. 2017;50(4):1701209.","journal-title":"Eur Respir J"},{"issue":"8","key":"2047_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S2213-2600(19)30172-9","volume":"7","author":"G Raghu","year":"2019","unstructured":"Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, et al. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir Med. 2019;7(8):657\u201364.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"2047_CR16","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2047_CR17","doi-asserted-by":"publisher","first-page":"5ra13","DOI":"10.1126\/scitranslmed.3000111","volume":"1","author":"AP Casta\u00f1o","year":"2009","unstructured":"Casta\u00f1o AP, Lin SL, Surowy T, Nowlin BT, Turlapati SA, Patel T, et al. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med. 2009;1(5):5ra13.","journal-title":"Sci Transl Med."},{"issue":"4","key":"2047_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jaci.2010.06.010","volume":"126","author":"AP Moreira","year":"2010","unstructured":"Moreira AP, Cavassani KA, Hullinger R, Rosada RS, Fong DJ, Murray L, et al. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J Allergy Clin Immunol. 2010;126(4):712-21.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2047_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.biocel.2010.10.013","volume":"43","author":"LA Murray","year":"2011","unstructured":"Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, Peng X, et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by serum amyloid P. Int J Biochem Cell Biol. 2011;43(1):154\u201362.","journal-title":"Int J Biochem Cell Biol"},{"issue":"20","key":"2047_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.87446","volume":"1","author":"N Nakagawa","year":"2016","unstructured":"Nakagawa N, Barron L, Gomez IG, Johnson BG, Roach AM, Kameoka S, et al. Pentraxin-2 suppresses c-Jun\/AP-1 signaling to inhibit progressive fibrotic disease. JCI Insight. 2016;1(20): e87446.","journal-title":"JCI Insight"},{"issue":"9","key":"2047_CR21","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1084\/jem.20160283","volume":"213","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, et al. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016;213(9):1723\u201340.","journal-title":"J Exp Med"},{"issue":"3","key":"2047_CR22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1183\/13993003.00850-2015","volume":"47","author":"B van den Blink","year":"2016","unstructured":"van den Blink B, Dillingh MR, Ginns LC, Morrison LD, Moerland M, Wijsenbeek M, et al. Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. Eur Respir J. 2016;47(3):889\u201397.","journal-title":"Eur Respir J"},{"issue":"5","key":"2047_CR23","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000479976","volume":"94","author":"U Costabel","year":"2017","unstructured":"Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, et al. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration. 2017;94(5):408\u201315.","journal-title":"Respiration"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02047-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02047-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02047-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T11:05:09Z","timestamp":1653131109000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02047-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2047"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02047-0","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The trial and clinical protocol was approved by the following local\/central ethics committees or institutional review boards: <i>Netherlands:<\/i> Medisch Ethische Toetsings Commissie Erasmus MC, Erasmus MC. <i>Germany:<\/i> Ethik-Kommission Medizinische Fakult\u00e4t Heidelberg, Universit\u00e4t Heidelberg; Ethik\u2010Kommission des Fachbereiches Medizin, Justus-Liebig-Universit\u00e4t Gie\u00dfen; Ethik\u2010Kommission, Universit\u00e4t Duisburg\u2010Essen; <i>Czech Republic<\/i>: Eticka komise IKEM a TN, Fakultn\u00ed Thomayerova Nemocnice. <i>Spain:<\/i> Research Ethics Committee for Medicinal Products, Hospital Universitari de Bellvitge; <i>Italy:<\/i> Azienda Ospedaliero-Universitaria Policlinico Vittorio; Comitato Etico, AO San Gerardo; <i>Switzerland:<\/i> Commission Cantonale d\u2019ethique de la recherche sur l'etre\u2010humain, Canton du Vaud; <i>USA<\/i>: Western Institutional Review Board (WIRB); Human Investigation Committee, Yale University; Human Research Protection Program IRB, University of California San Francisco; Human Research Protection Program IRB, University of Kansas Medical Center; University of Texas Southwestern Medical School IRB; University of Louisville Human Subjects Protection; Partners Human Research Committee, Partners Healthcare. Written informed consent to participate in the study was obtained from each patient or caregiver. An independent data and safety monitoring board provided oversight.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GR received support to his institution from Promedior (now a fully owned subsidiary of F. Hoffmann-La Roche, Ltd.) for study costs for the clinical trial; has received personal fees and other from Boehringer Ingelheim; consulting fees from Promedior and Veracyte; and other from Fibrogen, Roche-Genentech, Biogen, Bristol\u00a0Myers Squibb, Bellerophon, and Nitto.MJH has received research grant support from Promedior (now a fully owned subsidiary of F. Hoffmann-La Roche, Ltd.) during the conduct of the study; and outside the submitted work: a clinical trial research grant and a medical education grant from Boehringer Ingelheim, and clinical trial research grants from Roche-Genentech, Biogen, Fibrogen, and Global Blood Therapeutics; and personal fees from Boehringer Ingelheim and Roche-Genentech for serving as a contracted speaker.AWB has received grants and personal fees from Promedior (now a fully owned subsidiary of F. Hoffmann-La Roche, Ltd.) during the conduct of the study; and receipt of personal fees from Roche-Genentech (advisory board and speaker\u2019s bureau), Theravance Biopharma (consulting fees), and Pilot for IPF (honorarium for curriculum development for CME programs) outside the submitted work.JAG has received a research support grant from Promedior (now a fully owned subsidiary of F. Hoffmann-La Roche, Ltd.).LAH has received personal fees from Roche-Genentech and Boehringer Ingelheim for serving on an advisory board.MSW has received unrestricted grants and speaker fees from Boehringer Ingelheim and F. Hoffmann-La Roche, Ltd., and advisory board\/consulting fees from Galapagos, Novartis, Horizon, Bristol\u00a0Myers Squibb, Galecto, and Respivant. All grants and fees were paid to the Erasmus University Medical Center in Rotterdam, Netherlands.MV has received grants to her institution from Boehringer Ingelheim and F. Hoffmann-La Roche, Ltd., and consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Roche-Genentech.AP has received personal fees and support grants to his institution from Boehringer Ingelheim and Roche-Genentech.DEAO has received grants to her institution from Promedior (now a fully owned subsidiary of F. Hoffmann-La Roche, Ltd.) during the conduct of the study and grants from Roche-Genentech, Fibrogen, Boehringer Ingelheim, Biogen, Pliant, and Galecto outside the submitted work (clinical trial grants paid directly to Yale University).KCM has received research grants from the National Institutes of Health (NIH), Roche-Genentech, Parion, Nivalis, and Promedior (now a fully owned subsidiary of F. Hoffmann-La Roche, Ltd.); and personal fees for speaking engagements from the University of Nebraska and Practice Point Communications and National Jewish Health.MK has received independent grants to his institution and personal fees from F. Hoffmann-La Roche, Ltd. and Boehringer Ingelheim, and personal fees for consulting work from AstraZeneca, GlaxoSmithKline, Galapagos, and Chiesi. MK\u2019s institution has received research support from F. Hoffmann-La Roche, Ltd. and Boehringer Ingelheim.TB is an employee of Roche-Genentech.NK is an employee of F. Hoffmann-La Roche, Ltd.FD is an employee of F. Hoffmann-La Roche, Ltd.LR has received personal fees from F. Hoffmann-La Roche, Ltd., Fibrogen, Promedior (now a fully owned subsidiary of F. Hoffmann-La Roche, Ltd.; advisory board member), Sanofi, ImmuneWorks, Celgene, Nitto, Bristol\u00a0Myers Squibb (consulting), Shionogi (speaker), Boehringer Ingelheim (steering committee), and DynaMed (editorial activity).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}